Actuate Therapeutics Inc
Follow $ACTU
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ACTU by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ACTU moving today?
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ACTU overview
Related filings and maps
Congress activity in ACTU
No receipt-qualified Congressional disclosure is present for ACTU in the cached public ledger.
ACTU contract awards, year to date.
Public federal awards linked to this ticker.
ACTU lobbying filings, year to date.
Registered lobbying filings matched to Actuate Therapeutics Inc.